128102-16-9

Basic information

• Product Name: (R)-2-METHYL-PIPERAZINE-1,4-DICARBOXYLIC ACID 4-BENZYL ESTER 1-TERT-BUTYL ESTER
• Synonyms: R-1-BOC-4-CBZ-2-METHYLPIPERAZINE;(R)-2-METHYL-PIPERAZINE-1,4-DICARBOXYLIC ACID 4-BENZYL ESTER 1-TERT-BUTYL ESTER;(R)-4-Benzyl 1-Boc-2-Methylpiperazine-4-carboxylate
• CAS NO: 128102-16-9
• Molecular Formula: C₁₈H₂₆N₂O₄
• Molecular Weight: 334.41
• Mol File: 128102-16-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 435.4 °C at 760 mmHg
• Flash Point: 217.1 °C
• Appearance: /
• Density: 1.137 g/cm³
• Vapor Pressure: 8.81E-08mmHg at 25°C
• Refractive Index: 1.527
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-2-METHYL-PIPERAZINE-1,4-DICARBOXYLIC ACID 4-BENZYL ESTER 1-TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-METHYL-PIPERAZINE-1,4-DICARBOXYLIC ACID 4-BENZYL ESTER 1-TERT-BUTYL ESTER(128102-16-9)
• EPA Substance Registry System: (R)-2-METHYL-PIPERAZINE-1,4-DICARBOXYLIC ACID 4-BENZYL ESTER 1-TERT-BUTYL ESTER(128102-16-9)

Safety Data

• Hazardous Substances Data: 128102-16-9(Hazardous Substances Data)

Usage

General Description

The chemical (R)-2-methyl-piperazine-1,4-dicarboxylic acid 4-benzyl ester 1-tert-butyl ester is a compound that is used in organic synthesis and pharmaceutical research. It is a derivative of piperazine and contains a benzyl ester and a tert-butyl ester group. (R)-2-METHYL-PIPERAZINE-1,4-DICARBOXYLIC ACID 4-BENZYL ESTER 1-TERT-BUTYL ESTER has potential applications in the development of new drugs and in the study of chemical reactions involving piperazine derivatives. Its structure and properties make it an interesting target for further research in the fields of medicinal chemistry and drug discovery.

InChI:InChI=1/C18H26N2O4/c1-14-12-19(10-11-20(14)17(22)24-18(2,3)4)16(21)23-13-15-8-6-5-7-9-15/h5-9,14H,10-13H2,1-4H3/t14-/m1/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 109-07-9 (RS)-2-methylpiperazine 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 1207455-08-0 tert-butyl 4-(4-(9-(4-fluorophenyl)-3-oxo-3,7,8,9-tetrahydro-2H-pyrido[4,3,2-de]phthalazin-8-yl)benzyl)-2-methylpiperazine-1-carboxylate 
• 1207455-06-8 9-(4-fluorophenyl)-8-(4-((3-methylpiperazin-1-yl)methyl)phenyl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one 
• 120737-78-2 tert-butyl 2-methylpiperazine-1-carboxylate 

Relevant articles and documents

Optimization of 5-substituted thiazolyl ureas and 6-substituted imidazopyridines as potential HIV-1 latency reversing agents

A persistent latent reservoir of virus in CD4+ T cells is a major barrier to cure HIV. Activating viral transcription in latently infected cells using small molecules is one strategy being explored to eliminate latency. We previously described the use of a FlpIn.FM HEK293 cellular assay to identify and then optimize the 2-acylaminothiazole class to exhibit modest activation of HIV gene expression. Here, we implement two strategies to further improve the activation of viral gene expression and physicochemical properties of this class. Firstly, we explored rigidification of the central oxy-carbon linker with a variety of saturated heterocycles, and secondly, investigated bioisosteric replacement of the 2-acylaminothiazole moiety. The optimization process afforded lead compounds (74 and 91) from the 2-piperazinyl thiazolyl urea and the imidazopyridine class. The lead compounds from each class demonstrate potent activation of HIV gene expression in the FlpIn.FM HEK293 cellular assay (both with LTR EC50s of 80 nM) and in the Jurkat Latency 10.6 cell model (LTR EC50 220 and 320 nM respectively), but consequently activate gene expression non-specifically in the FlpIn.FM HEK293 cellular assay (CMV EC50 70 and 270 nM respectively) manifesting in cellular cytotoxicity. The lead compounds have potential for further development as novel latency reversing agents.

METHODS OF USING DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE)POLYMERASE (PARP)

Provided herein are methods of treating cancer comprising administering a topoisomerase inhibitor, temozolomide, or a platin in combination with a Compound of Formula (I) or Formula (II), where the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein.